NCT01497327View on ClinicalTrials.gov

Open-Label Hepatic Impairment Study

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Hepatitis C
Interventions
DRUG

PSI-352938

PSI-352938 300mg once daily (QD) for seven days

DRUG

PSI-7977

PSI-7977 400mg QD for seven days

Trial Locations (2)

Unknown

San Antonio

00927

San Juan

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01497327 - Open-Label Hepatic Impairment Study | Biotech Hunter | Biotech Hunter